Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Mini-Review Article

An Overview of the Treatment Contributions Measured Globally for the COVID-19 Outbreak

Author(s): Sheikh Saba Naz and Iqra Munir*

Volume 2, Issue 2, 2021

Published on: 19 October, 2020

Page: [198 - 203] Pages: 6

DOI: 10.2174/2666796701999201019154537

Abstract

Background: SARS CoV2 is a newly emerged animal beta coronavirus that causes respiratory illness. This infection has affected 212 countries to date and has been declared a pandemic by the World Health Organization. Due to the high transmission rate and lack of availability of any approved anti-viral drug, the formulation of a specific anti-viral therapy has now become a global emergency. Genomic studies have revealed a 79% identity of SARS CoV2 with SARS CoV and 50% identity with MERS CoV, which has given a clue point to test the drugs that were efficient against previously encountered beta coronaviruses. For this purpose, several clinical trials based on the knowledge of existing drugs are moving ahead. These therapies include chloroquine and hydroxychloroquine, remdesivir, corticosteroids therapy, favipiravir, ribavirin, lopinavir/ritonavir, anti-cytokine therapy, and convalescent sera.

Aim of the study: The purpose of this review is to give a pointer of contributions conducted globally, including strategies utilized for treatments, the pattern of dosage, adverse reactions, and effective outcomes from different drugs.

Methodology: Literature has been retrieved from PubMed, PubMed Central, ResearchGate, ScienceDirect, and Google Scholar, using a combination of keywords for extensive information.

Conclusion: Among all the drug options, Remdesivir and the use of Convalescent Sera have been considered as the safest options for treatment against COVID-19. Data from the ongoing clinical trials will be required for the formulation of a specific and approved anti-viral drug.

Keywords: Remdesivir, COVID-19 treatments, chloroquine, hydroxychloroquine, SARS CoV2 treatments, convalescent sera.

[2]
Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect 2020; 53(3): 436-43.
[http://dx.doi.org/10.1016/j.jmii.2020.03.034] [PMID: 32307245]
[3]
Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect 2020; 26(6): 729-34.
[http://dx.doi.org/10.1016/j.cmi.2020.03.026] [PMID: 32234451]
[4]
Worldometer. Coronavirus Update (Live): 21,376,872 Cases and 763,802 Deaths from COVID-19 Virus Pandemic – Worldometer. Available from: . https://www.worldometers.info/coronavirus/
[5]
Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020; 14(3): 241-6.
[http://dx.doi.org/10.1016/j.dsx.2020.03.011] [PMID: 32247211]
[6]
Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents 2020; 55(4)105945
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105945] [PMID: 32194152]
[7]
Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumato-logy. Nat Rev Rheumatol 2020; 16(3): 155-66.
[http://dx.doi.org/10.1038/s41584-020-0372-x] [PMID: 32034323]
[8]
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1): 72-3.
[http://dx.doi.org/10.5582/bst.2020.01047] [PMID: 32074550]
[9]
Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43(3): 185-8.
[PMID: 32164085]
[10]
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020; 57: 279-83.
[http://dx.doi.org/10.1016/j.jcrc.2020.03.005] [PMID: 32173110]
[11]
Gbinigie K, Frie K. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review BJGP Open 2020; 4(2)20X101069..
[http://dx.doi.org/10.3399/bjgpopen20X101069]
[12]
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 323(18): 1824-36.
[http://dx.doi.org/10.1001/jama.2020.6019] [PMID: 32282022]
[13]
Robin FE, Jeffrey AK. Chloroquine and hydroxychloroquine in covid-19. BMJ 2020; 369: m1432.
[http://dx.doi.org/10.1136/bmj.m1432]]
[14]
Rabby MII. Current drugs with potential for treatment of COVID-19: a literature review. J Pharm Pharm Sci 2020; 23(1): 58-64.
[http://dx.doi.org/10.18433/jpps31002] [PMID: 32251618]
[15]
Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020; 248117477
[http://dx.doi.org/10.1016/j.lfs.2020.117477] [PMID: 32119961]
[16]
Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382(24): 2327-36.
[http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]
[17]
Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 Coronavirus. Antimicrob Agents Chemother 2020; 64(5): e00399-20.
[http://dx.doi.org/10.1128/AAC.00399-20] [PMID: 32152082]
[18]
Yavuz SS, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci 2020; 50(SI-1): 611-9.
[http://dx.doi.org/10.3906/sag-2004-145] [PMID: 32293834]
[19]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[20]
Fda.gov. Fact sheet for healthcare providers emergency use authorization (EUA) of Veklury® (remdesivir) for hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg. Available from: . https://www.fda.gov/media/137566/download2020.
[21]
Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancer 2020; 14: 1023.
[http://dx.doi.org/10.3332/ecancer.2020.1023] [PMID: 32256706]
[22]
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
[23]
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395(10223): 473-5.
[http://dx.doi.org/10.1016/S0140-6736(20)30317-2] [PMID: 32043983]
[25]
Ma DY, Suthar MS. Mechanisms of innate immune evasion in re-emerging RNA viruses. Curr Opin Virol 2015; 12: 26-37.
[http://dx.doi.org/10.1016/j.coviro.2015.02.005] [PMID: 25765605]
[26]
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020; 14(1): 58-60.
[http://dx.doi.org/10.5582/ddt.2020.01012] [PMID: 32147628]
[27]
Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020; 6(10): 1192-8.
[http://dx.doi.org/10.1016/j.eng.2020.03.007] [PMID: 32346491]
[28]
Kandeel M, Al-Nazawi M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sci 2020; 251117627
[http://dx.doi.org/10.1016/j.lfs.2020.117627] [PMID: 32251634]
[29]
Kang S, Peng W, Zhu Y, et al. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents 2020; 55(5)105950
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105950] [PMID: 32234465]
[30]
Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting anti-viral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020; 295(20): 6785-97.
[http://dx.doi.org/10.1074/jbc.RA120.013679] [PMID: 32284326]
[31]
Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003; 289(21): 2801-9.
[http://dx.doi.org/10.1001/jama.289.21.JOC30885] [PMID: 12734147]
[32]
Choy KT, Wong AY, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res 2020; 178104786
[http://dx.doi.org/10.1016/j.antiviral.2020.104786] [PMID: 32251767]
[33]
Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. J Med Virol 2020; 92(7): 740-6.
[http://dx.doi.org/10.1002/jmv.25798] [PMID: 32227493]
[34]
US National Library of Medicine, Lopinavir/ ritonavir, ribavirin and IFN-beta combination for nCoV treatment Available from: https://clinicaltrials.gov/ct2/show/NCT04276688
[35]
Bhatnagar T, Murhekar MV, Soneja M, et al. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: protocol for restricted public health emergency use. Indian J Med Res 2020; 151(2 & 3): 184-9.
[http://dx.doi.org/10.4103/ijmr.IJMR_502_20] [PMID: 32362644]
[36]
Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: what we know so far. J Chin Med Assoc 2020; 83(6): 534-6.
[http://dx.doi.org/10.1097/JCMA.0000000000000318] [PMID: 32243270]
[37]
Yavuz SS, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci 2020; 50(1): 611-9.
[38]
Ye XT, Luo YL, Xia SC, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci 2020; 24(6): 3390-6.
[http://dx.doi.org/10.26355/eurrev_202003_20706] [PMID: 32271456]
[39]
New Straits Times,Thailand sees apparent success treating coronavirus with HIV drug Available from: https://www.nst.com.my/world/world/2020/02/562079/thand-sees-apparent-success-treating-coronavirus-hiv-drug
[40]
AAAS, WHO launches global megatrial of the four most promising coronavirus treatmentsAvailable from: https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments
[41]
Li Y, Xie Z, Lin W, et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19. (ELACOI). MedRxiv 2020; 2020: 1.
[http://dx.doi.org/10.1101/2020.03.19.20038984]]
[42]
Nutho B, Mahalapbutr P, Hengphasatporn K, et al. Why are lopinavir and ritonavir effective against the newly emerged Coronavirus 2019? Atomistic insights into the inhibitory mechanisms. Biochemistry 2020; 59(18): 1769-79.
[http://dx.doi.org/10.1021/acs.biochem.0c00160] [PMID: 32293875]
[43]
da Silva TJA. Convalescent plasma: a possible treatment of COVID-19 in India. Med J Armed Forces India 2020; 76(2): 236-7.
[http://dx.doi.org/10.1016/j.mjafi.2020.04.006] [PMID: 32296259]
[44]
Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130(4): 1545-8.
[http://dx.doi.org/10.1172/JCI138003] [PMID: 32167489]
[45]
Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323(16): 1582-9.
[http://dx.doi.org/10.1001/jama.2020.4783] [PMID: 32219428]
[46]
Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 2020; 368: m1256.
[http://dx.doi.org/10.1136/bmj.m1256.]
[47]
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020; 117(17): 9490-6.
[http://dx.doi.org/10.1073/pnas.2004168117] [PMID: 32253318]
[48]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[49]
Zhang Y, Yu L, Tang L, et al. A promising anti-cytokine-storm targeted therapy for COVID-19: the artificial-liver blood-purification system. Engineering 2020; 2020: 1.
[http://dx.doi.org/10.1016/j.eng.2020.03.006] [PMID: 32292628]
[50]
Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents 2020; 55(6)105982
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105982] [PMID: 32305588]
[51]
Cancio M, Ciccocioppo R, Rocco PRM, et al. Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. Cytotherapy 2020; 22(9): 474-81.
[http://dx.doi.org/10.1016/j.jcyt.2020.04.100]
[52]
Ingraham NE, Lotfi-Emran S, Thielen BK, et al. Immunomodulation in COVID-19. Lancet Respir Med 2020; 8(6): 544-6.
[http://dx.doi.org/10.1016/S2213-2600(20)30226-5] [PMID: 32380023]

© 2022 Bentham Science Publishers | Privacy Policy